drugset / Trial / NCT07589387
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
Not yet recruiting
2800 enrolled
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI) · collabUniversity of Abuja Teaching Hospital · collab
NaSingle-groupOpen-labelHealth-services research
Summary
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2029-04-30
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glimepiride | Small molecule | 8 mg | Oral |
| Subject | Metformin | Small molecule | 500 mg | Oral |
| Subject | Metformin | Small molecule | 1000 mg | Oral |